Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice

Amyloid

Volumn 21, Issue 1, 2014, Pages 45-53

  Kennel, Stephen J ^a   Macy, Sally ^a   Wooliver, Craig ^a   Huang, Ying ^a   Richey, Tina ^a   Heidel, Eric ^a   Wall, Jonathan S ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

AA amyloidosis; AEF; Clodronate liposomes; HuIL 6 mice; Macrophages; Peptides; SAA

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; AMYLOID ENHANCING FACTOR; CLODRONIC ACID; CONGO RED; IODINE 125; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BIREFRINGENCE; CATABOLISM; IMMUNOHISTOCHEMISTRY; KIDNEY PAPILLA; LIVER; MOUSE; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN; TISSUE SECTION; TRANSGENIC MOUSE;

AMYLOIDOSIS; ANIMALS; CLODRONIC ACID; GLYCOPROTEINS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LIVER; MICE; MICE, TRANSGENIC; PHAGOCYTES; RADIOPHARMACEUTICALS; SERUM AMYLOID A PROTEIN; SPLEEN; TISSUE DISTRIBUTION;

EID: 84896698070     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2013.876400     Document Type: Article

References (23)

1. Blancas-Mejia LM, Ramirez-Alvarado M. Systemic amyloidoses. Ann Rev Biochem 2013;82:745-74.
2. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M. Kinetics of amyloid deposition. 1. The effects of amyloidenhancing factor. Lab Invest 1982;47:139-46.
3. Kisilevsky R, Boudreau L. Kinetics of amyloid deposition. 1. The effects of amyloid-enhancing factor and splenectomy. Lab Invest 1983;48:53-9.
4. Wall JS, Kennel SJ, Paulus MJ, Gleason S, Gregor J, Baba J, Schell M, et al. Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis. Amyloid 2005;12:149-56.
5. Solomon A, Weiss DT, Schell M, Hrncic R, Murphy CL, Wall J, McGavin MD, et al. Transgenic mouse model of AA amyloidosis. Am J Pathol 1999;154:1267-72.
6. Elimova E, Kisilevsky R, Ancin JB. Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch. FASEB J 2009;23: 3436-48.
7. Nystrom SN, Westermark GT. AA-amyloid is cleared by endogenous immunological mechanisms. Amyloid 2012;19: 138-45.
8. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;469:93-7.
9. Wynn TA, Chawla A, Pollard JW. Marcophage biology in development, homeostasis and disease. Nature 2013;496: 445-55.
10. Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 1981; 10:805-15.
11. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 1996;224:855-62.
12. Pinto AJ, Stewart D, van Rooijen N, Morahan PS. Selective depletion of liver and splenic macrophages using liposomes encapsulating the drug dichloromethylene diphosphonate: effects on antimicrobial resistance. J Leukoc Biol 1991;49:579-86.
13. Van Rooijen N, van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res 2002;12: 81-94.
14. Kennel SJ, Woodward JD, Rondinone AJ, Wall J, Huang Y, Mirzadeh S. The fate of MAB-targeted Cd125mTe/ZnS nanoparticles in vivo. Nuc Med Biol 2008;35:501-14.
15. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin EC. The characterization of soluble amyloid prepared in water. J Clin Invest 1968;47:924-33.
16. Wall JS, Williams A, Richey T, Stuckey A, Huang Y, Wooliver C, Macy S, et al. A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo. PLoS One 2013;8:e66181.
17. Wall JS, Richey T, Stuckey A, Donnell R, Macy S, Martin EB, Williams A, et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci USA 2011;108:E586-94.
18. Hagan PL, Halpern SE, Chen A, Krishnan L, Frinke J, Bartholomew RM, David GS, et al. In vivo kinetics of radiolabeled monoclonal anti-CEA antibodies in animal models. J Nuc Med 1985;26:1418-23.
19. Snow AD, Bramson R, Mar H, Wight TN, Kisilevsky R. A temporal and ultrastructural relationship between heparin sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 1991;39:1321-30.
20. Arai K, Miura K, Baba S, Shirasawa H. Transformation from SAA2-fibrils to AA-fibrils in amyloid fibrillogenesis: in vivo observations in murine spleen using anti-SAA and anti-AA antibodies. J Pathol 1994;173:127-34.
21. Akar S, Yuksel F, Tunca M, Soysal O, Solmaz D, Gerdan V, Celik A, et al. Famalial Mediterranean fever: risk factors, causes of death and prognosis in the Cholchicine era. Medicine (Baltimore) 2012; 91:131-6.
22. Ozturk MA, Kanbay M, Kasapoglu B, Onat AM, Guz G, Furst DE, Ben-Chetrit E. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 2011;29:S77-86.
23. Lundmark K, Shariapanahi AV, Westermark GT. Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis. PLoS One 2013:8e79104; doi: 10.1371; PMID: 24236094.